UnitedHealth's shares surged 20% over the past month, trading around $389, driven by stronger-than-expected Q1 2026 results with revenue up 2% to $111.7 billion and adjusted EPS of $7.23. Despite Berkshire Hathaway's exit from its UNH stake, the company raised its full-year 2026 adjusted EPS guidance above $18.25, supported by growth at Optum and improved margins. Analysts remain optimistic, with a consensus 'Moderate Buy' rating and an average 12-month price target of $390, reflecting about 20% upside potential. Some risks remain, including Medicaid funding cuts, but overall UnitedHealth is viewed as fundamentally strong in the healthcare sector.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
